Histone Deacetylase Inhibitors in Combinatorial Anticancer Therapy (Paperback, 1st ed. 2020)

This book reviews the latest developments in the design, synthesis, and molecular mechanism of action of Histone Deacetylase (HDAC) inhibitors in the context of potential cancer therapy. HDAC inhibitors are emerging as promising anticancer drug molecules that promote growth arrest, differentiation and apoptosis of cancer cells with tumor selective toxicity. The book begins with an overview of various epigenetic modifying enzymes that are involved in cancer transition and progression; before exploring the potential of HDACs in cancer treatment. It provides a classification of HDAC inhibitors based on their structural attributes, and addresses HDAC-induced cytotoxicity.. Lastly, it discusses and assesses the rationale behind therapies that combine HDAC inhibitors with other anticancer agents to treat solid tumors. Given its scope, it offers a valuable resource for all researchers, clinicians, and students working in formulation, drug discovery, oncology, and personalized medicine.

General

Imprint:	Springer Verlag, Singapore
Country of origin:	Singapore
Release date:	November 2021
First published:	2020
Authors:	Shabir Ahmad Ganai
Dimensions:	235 x 155mm (L x W)
Format:	Paperback
Pages:	258
Edition:	1st ed. 2020
ISBN-13:	978-981-15-8181-6
Categories:	Books > Medicine > Pre-clinical medicine: basic sciences > Medical genetics Books > Science & Mathematics > Biology, life sciences > Biochemistry > General Books > Medicine > Clinical & internal medicine > Diseases & disorders > Oncology > General
LSN:	981-15-8181-9
Barcode:	9789811581816

Is the information for this product incomplete, wrong or inappropriate? Let us know about it.

Does this product have an incorrect or missing image? Send us a new image.

Is this product missing categories? Add more categories.

Review This Product

No reviews yet - be the first to create one!